Clinical trials have shown that PARP inhibitors can target tumors with homologous recombination deficiencies, such as BRCA-mutant cancers in breast cancer (NCT00494234) and ovarian cancer (NCT00753545) 63, 64. The gene discussed is PARP1; the disease is ovarian carcinoma.